SERUM HIGH SENSITIVITY C-REACTIVE PROTEIN AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AS CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES

被引:0
作者
Chantapet, Pranee [1 ]
Gat-ngern, Panisa [1 ]
Sawanpanyalert, Pathom [1 ]
Naulkhum, Pimpanita [2 ]
Jaikua, Pratin [2 ]
机构
[1] Minist Publ Hlth, Natl Inst Hlth, Dept Med Sci, Nonthaburi 11000, Thailand
[2] Bangkhayaeng Community Med Unit, Pathum Thani 12000, Thailand
关键词
high sensitivity C-reactive protein; non-HDL cholesterol; cardiovascular risk factor; type; 2; diabetes;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Type 2 diabetes mellitus is associated with increased cardiovascular risk. Two markers of cardiovascular risk assessment are high sensitivity C-reactive protein (hs-CRP) and non-high density lipoprotein cholesterol (non-HDL cholesterol). This case-control study attempted to compare levels of hs-CRP and non-HDL cholesterol between type 2 diabetic patients and non-diabetic individuals and investigate patients at high risk for cardiovascular disease, and analyze the association of hs-CRP levels with other cardiovascular risk factor in type 2 diabetes. A total of 123 type 2 diabetic patients [35 males and 88 females; median and (interquartile range) age of 57.0 (51.8-64.2) years; mean +/- SE body mass index of 26.4 +/- 0.4 kg/m(2), disease duration 5.7 +/- 0.5 years; and median and (interquartile range) hemoglobin A1C of 7.8 (6.7-9.4)%] and 92 non-diabetics [27 males and 65 females; median (interquartile range) age of 51.0 (45.0-59.0) years; mean +/- SE body mass index of 24.8 +/- 0.3 kg/m(2)] were studied. All subjects were interviewed by using the questionnaires included about lifestyle and medication used. Physical examinations and an over-night fasting blood collection were performed. Glucose, hemoglobin A1c, lipid profile, and hs-CRP levels were analyzed. The results indicate that serum levels of hs-CRP and non-HDL cholesterol in patients with type 2 diabetes were significantly higher than those in non-diabetics. Stratification into cardiovascular risk groups according to hs-CRP levels in combination with non-HDL cholesterol levels revealed that 72.4 percent of patients had high risk, 27.6 percent had intermediate risk, but none had low risk. However, an increased risk for CVD resulting in elevated hs-CRP (> 3 mg/l) of type 2 diabetes was significantly different from non-diabetes (odds ratio 1.95, 95% Confidence Interval 1.06-3.59, p-value 0.04). In type 2 DM, hs-CRP levels were significantly positive correlated with body mass index and fasting plasma glucose, inversely correlated with duration of diabetes. There were no significant correlation between hs-CRP and gender, age, waist circumference, blood pressure, lipid levels and hemoglobin A1C. In conclusion indicates that serum hs-CRP and non-HDL cholesterol levels in patient with type 2 diabetes are significantly higher than those in non-diabetics. The measurement of serum hs-CRP level as an adjunct to non-HDL cholesterol level may be useful for identifying cardiovascular risk in type 2 diabetes and should be evaluated in further prospective study.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 39 条
  • [1] Amanullah S., 2010, Jordan Journal of Biological Sciences (JJBS), V3, P7
  • [2] Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc10-S062, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc13-S067]
  • [3] Correlations of high-sensitivity C-reactive protein and atherosclerosis in Japanese type 2 diabetic patients
    Anan, Futoshi
    Masaki, Takayuki
    Umeno, Yoshikazu
    Iwao, Tetsu
    Yonemochi, Hidetoshi
    Eshima, Nobuoki
    Saikawa, Tetsunori
    Yoshimatsu, Hironobu
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 157 (03) : 311 - 317
  • [4] ARTISS JD, 1997, HDB LIPOPROTEIN TEST, P99
  • [5] C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes - The Strong Heart Study
    Best, LG
    Zhang, Y
    Lee, ET
    Yeh, JL
    Cowan, L
    Palmieri, V
    Roman, M
    Devereux, RB
    Fabsitz, RR
    Tracy, RP
    Robbins, D
    Davidson, M
    Ahmed, A
    Howard, BV
    [J]. CIRCULATION, 2005, 112 (09) : 1289 - 1295
  • [6] Blood pressure and inflammation in apparently healthy men
    Chae, CU
    Lee, RT
    Rifai, N
    Ridker, PM
    [J]. HYPERTENSION, 2001, 38 (03) : 399 - 403
  • [7] Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective
    Chan, Juliana C. N.
    Deerochanawong, Chaicharn
    Shera, A. Samad
    Yoon, Kun-Ho
    Adam, John M. F.
    Van Binh, Ta
    Chan, Siew-Pheng
    Fernando, Richard Elwyn
    Horn, Lee Chung
    Khue, Nguyen Thy
    Litonjua, Augusto D.
    Soegondo, Sidartawan
    Zimmet, Paul
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 75 (03) : 255 - 266
  • [8] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [9] Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension
    Choi, H
    Cho, DH
    Shin, HH
    Park, JB
    [J]. CIRCULATION JOURNAL, 2004, 68 (04) : 297 - 303
  • [10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497